16-HETE

• Description:

  16-HETE is arachidonic acid metabolite through subterminal hydroxylation by cytochrome P-450. 16-HETE exhibits vasodilatory and PMN inhibitory effects and serves as biomarker for early stages of non-alcoholic fatty liver disease[1][2][3].

• UNSPSC:

  12352211

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Na+/K+ ATPase

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/16-hete.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCCC (O) /C=C\C/C=C\C/C=C\C/C=C\CCCC (O) =O

• Molecular Formula:

  C20H32O3

• Molecular Weight:

  320.47

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations:

  [1]Bednar MM, et al., 16 (R) -hydroxyeicosatetraenoic acid, a novel cytochrome P450 product of arachidonic acid, suppresses activation of human polymorphonuclear leukocyte and reduces intracranial pressure in a rabbit model of thromboembolic stroke. Neurosurgery. 2000 Dec;47 (6) :1410-8; discussion 1418-9.|[2]Carroll MA, e al., Cytochrome P-450-dependent HETEs: profile of biological activity and stimulation by vasoactive peptides. Am J Physiol. 1996 Oct;271 (4 Pt 2) :R863-9.|[3]Maciejewska D, et al., Metabolites of arachidonic acid and linoleic acid in early stages of non-alcoholic fatty liver disease--A pilot study. Prostaglandins Other Lipid Mediat. 2015 Sep;121 (Pt B) :184-9.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  128914-46-5